Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Rhea-AI Summary
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment, has announced its participation in the 7th Annual Evercore ISI HealthCONx Healthcare Conference. Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will engage in a fireside chat on December 5, 2024, at 12:55 pm ET in Miami, Florida. The conference runs from December 3-5, and a live webcast will be available on the company's investor website, with a replay accessible for approximately 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, HOWL declined 1.80%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 12:55 pm ET on Thursday, December 5, 2024, at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, taking place December 3-5 in Miami, Florida.
A live webcast link for the Evercore ISI HealthCONx Conference fireside chat will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact:
John Norton
Precision AQ
212.362.1200
john.norton@precisionaq.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the Evercore ISI HealthCONx Conference 2024?
Where can I watch Werewolf Therapeutics (HOWL) Evercore ISI Conference presentation?
Which Werewolf Therapeutics (HOWL) executives are presenting at the 2024 Evercore Conference?
How long will the Werewolf Therapeutics (HOWL) Evercore presentation replay be available?
